Literature DB >> 24334684

Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity.

Marc Kirchmeier1, Anne-Catherine Fluckiger, Catalina Soare, Jasminka Bozic, Barthelemy Ontsouka, Tanvir Ahmed, Abebaw Diress, Lenore Pereira, Florian Schödel, Stanley Plotkin, Charlotte Dalba, David Klatzmann, David E Anderson.   

Abstract

A prophylactic vaccine to prevent the congenital transmission of human cytomegalovirus (HCMV) in newborns and to reduce life-threatening disease in immunosuppressed recipients of HCMV-infected solid organ transplants is highly desirable. Neutralizing antibodies against HCMV confer significant protection against infection, and glycoprotein B (gB) is a major target of such neutralizing antibodies. However, one shortcoming of past HCMV vaccines may have been their failure to induce high-titer persistent neutralizing antibody responses that prevent the infection of epithelial cells. We used enveloped virus-like particles (eVLPs), in which particles were produced in cells after the expression of murine leukemia virus (MLV) viral matrix protein Gag, to express either full-length CMV gB (gB eVLPs) or the full extracellular domain of CMV gB fused with the transmembrane and cytoplasmic domains from vesicular stomatitis virus (VSV)-G protein (gB-G eVLPs). gB-G-expressing eVLPs induced potent neutralizing antibodies in mice with a much greater propensity toward epithelial cell-neutralizing activity than that induced with soluble recombinant gB protein. An analysis of gB antibody binding titers and T-helper cell responses demonstrated that high neutralizing antibody titers were not simply due to enhanced immunogenicity of the gB-G eVLPs. The cells transiently transfected with gB-G but not gB plasmid formed syncytia, consistent with a prefusion gB conformation like those of infected cells and viral particles. Two of the five gB-G eVLP-induced monoclonal antibodies we examined in detail had neutralizing activities, one of which possessed particularly potent epithelial cell-neutralizing activity. These data differentiate gB-G eVLPs from gB antigens used in the past and support their use in a CMV vaccine candidate with improved neutralizing activity against epithelial cell infection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24334684      PMCID: PMC3910943          DOI: 10.1128/CVI.00662-13

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  22 in total

Review 1.  Is there a formula for an effective CMV vaccine?

Authors:  Stanley A Plotkin
Journal:  J Clin Virol       Date:  2002-08       Impact factor: 3.168

2.  Humoral immunity targeting site I of antigenic domain 2 of glycoprotein B upon immunization with different cytomegalovirus candidate vaccines.

Authors:  Fredrika Axelsson; Stuart P Adler; Alain Lamarre; Mats Ohlin
Journal:  Vaccine       Date:  2007-11-09       Impact factor: 3.641

Review 3.  Infection in solid-organ transplant recipients.

Authors:  Jay A Fishman
Journal:  N Engl J Med       Date:  2007-12-20       Impact factor: 91.245

4.  Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism.

Authors:  Dai Wang; Thomas Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-30       Impact factor: 11.205

5.  Human cytomegalovirus labeled with green fluorescent protein for live analysis of intracellular particle movements.

Authors:  Kerstin Laib Sampaio; Yolaine Cavignac; York-Dieter Stierhof; Christian Sinzger
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

6.  Function of human cytomegalovirus glycoprotein B: syncytium formation in cells constitutively expressing gB is blocked by virus-neutralizing antibodies.

Authors:  S Tugizov; D Navarro; P Paz; Y Wang; I Qadri; L Pereira
Journal:  Virology       Date:  1994-06       Impact factor: 3.616

7.  Vaccine prevention of maternal cytomegalovirus infection.

Authors:  Robert F Pass; Changpin Zhang; Ashley Evans; Tina Simpson; William Andrews; Meei-Li Huang; Lawrence Corey; Janie Hill; Elizabeth Davis; Cynthia Flanigan; Gretchen Cloud
Journal:  N Engl J Med       Date:  2009-03-19       Impact factor: 91.245

Review 8.  Human CMV vaccine trials: what if CMV caused a rash?

Authors:  Stuart P Adler
Journal:  J Clin Virol       Date:  2007-12-21       Impact factor: 3.168

9.  Cytomegalovirus vaccine strain towne-derived dense bodies induce broad cellular immune responses and neutralizing antibodies that prevent infection of fibroblasts and epithelial cells.

Authors:  Corinne Cayatte; Kirsten Schneider-Ohrum; Zhaoti Wang; Alivelu Irrinki; Nga Nguyen; Janine Lu; Christine Nelson; Esteban Servat; Lorraine Gemmell; Andrzej Citkowicz; Yi Liu; Gregory Hayes; Jennifer Woo; Gary Van Nest; Hong Jin; Gregory Duke; A Louise McCormick
Journal:  J Virol       Date:  2013-08-07       Impact factor: 5.103

10.  Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection.

Authors:  Xiaohong Cui; Benjamin P Meza; Stuart P Adler; Michael A McVoy
Journal:  Vaccine       Date:  2008-08-19       Impact factor: 3.641

View more
  34 in total

1.  A trimeric capable gB CMV vaccine provides limited protection against a highly cell associated and epithelial tropic strain of cytomegalovirus in guinea pigs.

Authors:  K Yeon Choi; Nadia S El-Hamdi; Alistair McGregor
Journal:  J Gen Virol       Date:  2021-03-17       Impact factor: 3.891

2.  Immunization in Canada: Update for 2015.

Authors:  Donna M MacDougall; Scott A Halperin
Journal:  J Can Chiropr Assoc       Date:  2016-03

3.  Production of Cytomegalovirus Dense Bodies by Scalable Bioprocess Methods Maintains Immunogenicity and Improves Neutralizing Antibody Titers.

Authors:  Kirsten Schneider-Ohrum; Corinne Cayatte; Yi Liu; Zhaoti Wang; Alivelu Irrinki; Floro Cataniag; Nga Nguyen; Stacie Lambert; Hui Liu; Shahin Aslam; Greg Duke; Michael P McCarthy; Louise McCormick
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

4.  Cell Fusion Induced by a Fusion-Active Form of Human Cytomegalovirus Glycoprotein B (gB) Is Inhibited by Antibodies Directed at Antigenic Domain 5 in the Ectodomain of gB.

Authors:  Nina Reuter; Barbara Kropff; Julia Karin Schneiderbanger; Mira Alt; Adalbert Krawczyk; Christian Sinzger; Thomas H Winkler; William J Britt; Michael Mach; Marco Thomas
Journal:  J Virol       Date:  2020-08-31       Impact factor: 5.103

Review 5.  Cytomegalovirus Vaccines: Current Status and Future Prospects.

Authors:  K M Anderholm; C J Bierle; M R Schleiss
Journal:  Drugs       Date:  2016-11       Impact factor: 9.546

Review 6.  Progress toward Development of a Vaccine against Congenital Cytomegalovirus Infection.

Authors:  Mark R Schleiss; Sallie R Permar; Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2017-12-05

Review 7.  The history of vaccination against cytomegalovirus.

Authors:  Stanley Plotkin
Journal:  Med Microbiol Immunol       Date:  2015-03-20       Impact factor: 3.402

Review 8.  The immunological underpinnings of vaccinations to prevent cytomegalovirus disease.

Authors:  A Louise McCormick; Edward S Mocarski
Journal:  Cell Mol Immunol       Date:  2014-12-29       Impact factor: 11.530

9.  A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells.

Authors:  Michael A McVoy; Ronzo Lee; Frances M Saccoccio; Jukka Hartikka; Larry R Smith; Rohit Mahajan; Jian Ben Wang; Xiaohong Cui; Stuart P Adler
Journal:  Vaccine       Date:  2015-10-24       Impact factor: 3.641

10.  Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response.

Authors:  Xinle Cui; Zhouhong Cao; Shuishu Wang; Ronzo B Lee; Xiao Wang; Haruhiko Murata; Stuart P Adler; Michael A McVoy; Clifford M Snapper
Journal:  Vaccine       Date:  2018-08-03       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.